Opioid Quantity Limit Overrides
Indications for Prior Authorization
Criteria
Authorization will be issued for long-term therapy. *For oral fentanyl products, please refer to the drug-specific quantity limit override criteria in the “Oral Fentanyl Products” guideline.
Administrative
Length of Approval: 5 Year(s)
For diagnosis of For Malignant Cancer Pain
- In the absence of an opioid-specific quantity limit override guideline, the following approval criteria will be used:
- Diagnosis of malignant (cancer) pain*
Administrative
Length of Approval: 1 Year(s)
For diagnosis of For Non-Malignant Pain
- In the absence of an opioid-specific quantity limit override guideline, the following approval criteria will be used:
- Prescribed by a pain specialist or by pain management consultation AND
- The prescriber maintains and provides chart documentation of the patient’s evaluation, including all of the following:
- An appropriate patient medical history and physical examination
- A description of the nature and intensity of the pain
- Documentation of appropriate dose escalation
- Documentation of ongoing, periodic review of the course of opioid therapy
- An updated, comprehensive treatment plan (the treatment plan should state objectives that will be used to determine treatment success, such as pain relief or improved physical and/or psychosocial function)
- Verification that the risks and benefits of the use of the controlled substance have been discussed with the patient, significant other(s), and/or guardian
P & T Revisions
2024-11-06, 2023-10-19, 2022-10-19, 2022-01-14, 2021-10-28, 2021-09-28, 2021-05-21, 2020-10-29, 2019-10-29
References
Revision History
- 2024-11-06: 2024 Annual Review. No criteria changes.
- 2023-10-19: Annual review
- 2022-10-19: Annual review
- 2022-01-14: Annual Review
- 2021-10-28: Annual Review
- 2021-09-28: Addition of EHB formulary to guideline, no changes to criteria
- 2021-05-21: Addition of EHB formulary to guideline, no changes to criteria
- 2020-10-29: UM annual review.
- 2019-10-29: 2019 Annual Review